Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference GlobeNewswire - Thu Dec 18, 8:00AM CST

JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University GlobeNewswire - Tue Dec 9, 8:00AM CST

- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium GlobeNewswire - Thu Dec 4, 8:00AM CST

JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer GlobeNewswire - Tue Dec 2, 8:00AM CST

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that the FDA...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate in December Investor Conferences GlobeNewswire - Mon Dec 1, 8:00AM CST

JERUSALEM, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 20, 3:05PM CST

-  Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study - - Newly received r adioactive m aterial l icense for New Hampshire f acility ...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London GlobeNewswire - Tue Nov 11, 7:30AM CST

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness GlobeNewswire - Tue Oct 21, 7:30AM CDT

-  Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ® , the innovative alpha-radiation cancer therapy designed for potent...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial GlobeNewswire - Tue Sep 2, 7:30AM CDT

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)
Alpha Tau to Participate in Five September Investor Conferences GlobeNewswire - Wed Aug 27, 7:30AM CDT

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 5.07 (+1.20%)
DRTSW : 0.3350 (+1.52%)

Barchart Exclusives

The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside Barchart - Sat Dec 20, 11:00AM CST
These biotech bets are only for investors who can stomach volatility. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot